Disclaimer: This guide is for educational purposes only and does not constitute legal advice. Regulatory compliance requirements vary by state and employer. Always consult your company's legal and compliance team before making claims about specific compounds.
The April 15, 2026 FDA announcement created a genuine compliance gray zone. Seven peptides were temporarily removed from the Category 2 restricted list while the July advisory panel review proceeds. Some compounding pharmacies have begun producing these compounds again. Sales reps are fielding questions from prescribers. And the rules governing what you can say have not been updated to match the rapidly shifting landscape.
This guide gives you the framework to navigate those conversations accurately, protect your organization, and serve your prescriber clients well.
The Regulatory Framework You Need to Understand
503A vs 503B — The Key Distinction
Most peptide compounding happens under two frameworks. 503A pharmacies are traditional compounding pharmacies that compound patient-specific medications based on a valid prescription. 503B outsourcing facilities operate at larger scale, compound without patient-specific prescriptions, and are subject to FDA oversight similar to drug manufacturers.
The rules for what each can compound differ significantly, and the recent changes affect them differently. When a prescriber asks whether a compound is available, the honest answer depends entirely on which type of facility your pharmacy operates under.
Category 1 vs Category 2 — What It Actually Means
The FDA's 503A Bulks List has two categories. Category 1 substances are those the FDA has determined can be used in compounding. Category 2 substances are nominated for inclusion but have been placed in a restricted category, typically because of safety or clinical need questions.
The April 15 announcement means the seven peptides are being temporarily moved off the Category 2 restricted list while the July panel deliberates. This does not mean they have been added to Category 1. It creates an interim status that your legal team needs to assess before your pharmacy begins or resumes production.
The critical distinction: "Not currently restricted" is not the same as "approved for compounding." Know which status applies to each compound in your formulary before representing its availability to prescribers.
Current Status by Compound
| Compound | Current Status | 503A Compounding | 503B Compounding |
|---|---|---|---|
| BPC-157 | Interim gray zone | Consult legal | Generally not permitted |
| TB-500 (Thymosin B4) | Interim gray zone | Consult legal | Generally not permitted |
| Ipamorelin | Interim gray zone | Consult legal | Generally not permitted |
| Semaglutide | Restricted | Not permitted (shortage ended) | Limited 503B provisions only |
| Tirzepatide | Restricted | Not permitted (shortage ended) | Limited 503B provisions only |
| Sermorelin | Category 1 | Permitted with Rx | Permitted |
| Oxytocin | Category 1 | Permitted with Rx | Permitted |
Status as of April 18, 2026. This table will be updated after the July 23-24 FDA panel.
The Can / Cannot Framework
Regardless of a compound's compounding status, FDA regulations on drug claims apply. Here is the practical breakdown for sales conversations:
| ✓ You CAN Say | ✗ You CANNOT Say |
|---|---|
| "This compound is available from our pharmacy with a valid prescription from a licensed prescriber." | "This compound treats [condition]." — Making disease treatment claims on an unapproved drug is prohibited regardless of compounding status. |
| "Research suggests this compound may support [general area, e.g., tissue repair pathways] — here are the relevant studies." | "This is FDA approved for..." — No compounded peptide is FDA approved. Ever. This is a significant compliance violation. |
| "Our pharmacy compounds this to the prescriber's specifications using USP-grade ingredients." | "This is safe and effective." — Efficacy and safety claims for unapproved compounds are prohibited without clinical trial data supporting them. |
| "Many practitioners are finding this compound useful in their [area] practices — would you like to see the research?" | "My patients/clients have had great results with this for [condition]." — Testimonial-style efficacy claims for unapproved drugs are prohibited in promotional contexts. |
| "This compound is currently available for compounding — I'd recommend confirming the latest regulatory status with your compliance team." | "The FDA approved this for compounding." — The interim Category 2 removal is not an approval. Representing it as such is misleading and creates liability. |
| "Here is the current research on mechanism of action." Then provide actual citations. | Sharing patient outcome claims, before/after marketing materials, or influencer content as part of your sales presentation. |
Navigating the July Panel Window Specifically
The period between now and the July 23-24 panel vote is the most compliance-sensitive window. Here is how to frame conversations during this period:
When a prescriber asks: "Is BPC-157 legal now?"
Accurate answer: "The FDA temporarily removed it from the restricted Category 2 list while an advisory panel reviews it this July. Our pharmacy's legal team has assessed this as permitting compounding under 503A during this interim period with a valid prescription. The formal determination comes after the July panel."
What not to say: "Yes, it's legal now" or "The FDA approved it." Neither is accurate.
When a prescriber asks: "What does the July panel mean?"
Accurate answer: "The panel will vote on whether to recommend adding these compounds to the approved Category 1 bulks list. A positive vote starts the formal rulemaking process — it doesn't immediately change status. Full clarity is likely mid-to-late 2026 at earliest."
When a prescriber asks about efficacy evidence
Your strongest position is honest about the evidence tier. For BPC-157: "The animal model data on tissue repair is substantial and comes from multiple independent research groups. Human clinical trial data is limited — there are no completed Phase II or III trials. Most practitioners using it are doing so based on preclinical evidence and clinical observation."
This framing is both accurate and credible. Overstating efficacy to close a sale creates liability and erodes the trust that drives long-term prescriber relationships.
State-Level Variation
Compounding pharmacy regulation involves both federal FDA oversight and state pharmacy board oversight. State boards vary significantly in how they interpret federal compounding rules. Some states have issued their own guidance on peptide compounding that is more or less restrictive than the federal baseline.
Before representing the availability of any compound, confirm your state pharmacy board's current position. This is especially important in California, New York, and Florida, which have historically maintained stricter positions on compounding.
Social Media and Off-Label Promotion
A specific compliance risk area for sales reps in 2026: personal social media use. If you are active on Instagram, LinkedIn, or X discussing peptide compounds, the same promotional standards apply. Sharing influencer content that makes unapproved drug claims, posting before/after results attributing outcomes to specific compounds, or tagging your pharmacy in posts that make efficacy claims can create regulatory and employment liability.
A safe social media posture: share research citations, regulatory updates, and educational content. Do not share patient outcomes or efficacy claims tied to specific compounds.
The Conversation That Builds Long-Term Relationships
The practitioners worth having as long-term clients are exactly the ones who will respect and trust a rep who is honest about the evidence base, clear about regulatory status, and proactive about compliance. The compounding pharmacy space has a credibility problem with some prescribers because of years of overclaiming. Being the rep who does not overclaim is a differentiator, not a liability.
Lead with the science. Acknowledge the evidence gaps. Confirm the regulatory status accurately. That approach builds the kind of prescriber trust that drives sustainable business.
Next update: This guide will be updated the week of July 28, 2026 following the FDA advisory panel vote. Subscribe to the Peptide Academy Professional briefing to receive it automatically.